Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. - Wikidata - wikimedia - TriplyDB

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.

http://www.wikidata.org/entity/Q43921041

about

Cancer concepts and principles: primer for the interventional oncologist-part II New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma).Gastrinomas: advances in diagnosis and management.Zollinger-Ellison syndrome: classical considerations and current controversies.Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Comparison study of gastrinomas between gastric and non-gastric origins.Antitumor effects of somatostatin analogs in neuroendocrine tumors.Treatment of Zollinger-Ellison syndrome.The expanding role of somatostatin analogs in the management of neuroendocrine tumors.Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor.Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls Gastrinoma (duodenal and pancreatic).Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.Medical management of pancreatic neuroendocrine tumors.Diagnosis and Treatment of Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1).Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Future perspectives on neuroendocrine tumors.Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors Treatment options for unresectable neuroendocrine liver metastases.Systemic therapy for advanced pancreatic neuroendocrine tumors Zollinger-Ellison syndrome: recent advances and controversies.Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified?Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.Medical treatment of gastroenteropancreatic neuroendocrine tumors.Management of the hormonal syndrome of neuroendocrine tumors.Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas.Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease.The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?SiRNA-Mediated Down-Regulation of CLIC4 Gene Inhibits Cell Proliferation and Accelerates Cell Apoptosis of Mouse Liver Cancer Hca-F and Hca-P Cells.

P2860

Q27010961-C0C6E7B3-781C-4849-94F6-E90B27E346CF Q30364864-93B82DF0-B112-43BE-9FEE-AE2AA6D25959 Q33753449-3A9E7EE7-FCA6-4A2A-A6B6-38DCB7A53BC6 Q33782024-605881DA-11A3-4E3C-AF0B-546D6366C5B2 Q33801620-C68CAE35-86A1-469E-851B-0996AFB43ED4 Q34358058-61D0209B-349E-4CE4-BFD7-98C2E2A7974A Q34390574-BB36BF28-1A1E-4CD6-AEBC-B5E08F205F3C Q34978826-7AB34704-9440-4FD2-926A-877DE52E54E7 Q34987688-A4AC560E-B8F0-4D26-9AC1-5F396049B7D8 Q35065094-AE6C82B2-D1FD-4FD4-B78B-3EDCD5B457EF Q35550939-E16E1714-E737-4049-8EF4-9B2E25982A10 Q35760798-65F5064C-5548-46D2-A08B-9A1AE8F2DE77 Q35774521-EA56AF53-2E42-4044-A6BF-312CADA95851 Q36051476-9C1F0347-07B3-4E7E-A85F-DA6C1EF23397 Q36285347-D176390B-4E81-43A4-B4E6-ABD4302085E9 Q36347272-F4E2ED12-4C84-46A5-8129-CC73F0C560B1 Q36565495-5AD23137-2274-4692-BFE8-EB3F57CBC8E9 Q36582343-FA150ACD-414C-4777-9E41-EFA3C118A2C5 Q36741116-FA003AE6-ED8A-4F5C-9675-92701D389D41 Q36882123-8C84E983-1E61-44AE-A3EE-1171C3EBDCAB Q37009032-410E62A3-A719-449A-9DE3-FA5428C0F96F Q37016985-61093423-6B07-440E-A12B-B76EAC610512 Q37056120-048113B7-08B0-47E6-BDEC-D793C85A24B1 Q37564373-B5E4C7BA-F8C5-4E30-8BFE-9DCF1C0191B6 Q37843819-1D38682C-FFC9-4BAC-A43E-467A31EADF59 Q37889407-0B8A1600-1842-4A6D-A19C-F98494C86B00 Q38014498-F302B91F-1464-490E-968B-6E38F75AE4D1 Q38079854-6ECF1F41-8A18-4C60-97C3-EC696B2116D2 Q38150165-5C21EFD1-EA52-4BAF-B9A9-708EF0F92560 Q38658730-A250067C-7F3D-4540-A839-11002967A1BF Q38754421-A8D110DF-1BF1-4759-81F8-95312CD1C46F Q39217510-5B7B66A0-D858-4204-9A35-2FF35F77AD01 Q39254045-87CFFB5B-9CAA-4DFA-8246-440519DF6FA7 Q41832570-D5E99680-1543-473B-8A23-41638CF762A0 Q42469904-2C1429AC-B12A-41CF-A6BD-1A1B0A831221 Q43121154-1D4E7BD5-E192-4732-B656-CF0BCCA41CB8 Q46111876-6BF7588F-5869-4981-BE24-A5F43C856E4F Q46599160-8539B0CB-4538-40AC-BF71-6892A44301EF Q47822235-36CEE1C1-999C-4B85-AE35-A8F9B478BCBD Q48245740-96BC11EB-C7E7-45C6-BC26-B2C1AC0AEE69

P2860

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.

http://www.wikidata.org/entity/Q43921041

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Prospective study of the antit ...... ressive metastatic gastrinoma.

@en

Prospective study of the antit ...... ressive metastatic gastrinoma.

@nl

type

label

Prospective study of the antit ...... ressive metastatic gastrinoma.

@en

Prospective study of the antit ...... ressive metastatic gastrinoma.

@nl

prefLabel

Prospective study of the antit ...... ressive metastatic gastrinoma.

@en

Prospective study of the antit ...... ressive metastatic gastrinoma.

@nl

P1433

Q43921041-591AAEEB-CBF1-47D5-968D-F6DE30A221AB

P1476

Q43921041-413ABE2F-9213-43EF-8BDE-906A9E099055

P2093

Q43921041-2301C2EC-35CC-4379-8CB2-6FF8A95491EF

Q43921041-7B660DB0-DD03-4A66-9928-8A423A153250

Q43921041-8827FAD8-DE50-4726-96DF-236D62A4FE3D

Q43921041-88D23D5A-19D4-4A6E-B85C-2E97C83F239A

Q43921041-B514375C-603E-4A16-8E2C-E6448748BD2A

Q43921041-ECFF24AD-8AE7-4B1A-A948-4C7447402B84

Q43921041-F6B93993-025F-4888-8B5C-B95159680A4B

P2860

Q43921041-00C5617C-723A-419D-9513-D06AFDB2A0A9

Q43921041-11A9AB53-145A-4F24-8DA1-91F29A2C8097

Q43921041-14B0B57F-825B-40D6-A9E6-E4154172F3BC

Q43921041-2726D77D-211C-4F01-85A0-8591298604DB

Q43921041-2EB8015B-ADD4-4FA0-8F53-D6D5F68F7C49

Q43921041-344DE431-534F-4F50-B0FD-A04DFD47CA8C

Q43921041-43792C71-EEBE-433A-817E-4DF220172499

Q43921041-4F9E3E96-FFDE-436D-940A-6D11D64503FB

Q43921041-50FB7397-9312-4C5F-BFB7-127B270647B1

Q43921041-54208DBF-FAED-431C-B4C2-A55CE55B11F2

P304

Q43921041-C5EBCDAE-A71E-455E-AEE3-FDE72120EC76

P31

Q43921041-F12FAB89-9F5F-4D5B-9BC2-E6FDA0510D55

P356

Q43921041-1731B714-CFFE-4A18-84C7-881A1CD1B56A

P407

Q43921041-D70F7B29-93BC-4F29-A8DC-37D0D5B1DCBC

P433

Q43921041-3BC0F0A6-51E5-47BE-BC11-495A1D49867A

P478

Q43921041-52AAEFF7-722E-4E39-89E6-801A8ACD76F7

P577

Q43921041-3CAE0C33-DAD6-499D-9D88-CFD3FD7CE635

P5875

Q43921041-0F826E52-D022-4836-A852-AE3847A7F3E9

P698

Q43921041-18626B52-58A9-4728-9F11-F9F869A20DC7

P356

P1433

P1476

Prospective study of the antit ...... ressive metastatic gastrinoma.

@en

P2093

Adeline Louie

http://www.w3.org/2001/XMLSchema#string

Alaa Abou-Saif

http://www.w3.org/2001/XMLSchema#string

Fathia Gibril

http://www.w3.org/2001/XMLSchema#string

Homayoun Shojamanesh

http://www.w3.org/2001/XMLSchema#string

Jeremiah V Ojeaburu

http://www.w3.org/2001/XMLSchema#string

Robert T Jensen

http://www.w3.org/2001/XMLSchema#string

Showkat Bashir

http://www.w3.org/2001/XMLSchema#string

P2860

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook.

Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment.

Natural history of neuroendocrine enteropancreatic tumors.

Chemotherapy in the treatment of neuroendocrine malignant tumors.

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.

Pancreatic endocrine tumors.

Antiproliferative effect of somatostatin and analogs.

Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature.

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

P304

331-343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.10195

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11464102

http://www.w3.org/2001/XMLSchema#string

P698

11900219

http://www.w3.org/2001/XMLSchema#string